NCT06002555View on ClinicalTrials.gov

Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

September 22, 2023

Study Completion Date

September 22, 2023

Conditions
Healthy Subjects
Interventions
DRUG

Apraglutide

Peptide analogue of GLP-2

Trial Locations (1)

Unknown

ICON Clinical Research Unit, Groningen

All Listed Sponsors
lead

VectivBio AG

INDUSTRY

NCT06002555 - Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation | Biotech Hunter | Biotech Hunter